



Date: May 14, 2025

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 (“the Listing Regulations”)

With reference to our earlier communication dated May 11, 2025, we wish to inform you that the Company has received an order from Office of the Dy. Commissioner of Income Tax, Central Circle 29, New Delhi dated 9th May, 2025 (Received on 13th & 14th May, 2025 through IT Portal).

The detailed disclosure required as per Regulation 30 of the Listing Regulations read with Master Circular No. SEBI/HO/CFD/ PoD2/CIR/P/0155 dated November 11, 2024 as amended from time to time is enclosed herewith as Annexure-I.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain

Company Secretary and Compliance Officer



Sr. No.	Details of event that needs to be provided	Details
1	Name of the authority	Office of the Dy. Commissioner of Income Tax, Central Circle 29, New Delhi ('IT Authority')
2	Nature and details of the action(s) taken, initiated or order(s) passed;	AYs 2018-19, 2020-21 & 2022-23
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;	Orders dated 9 th May, 2025 (Received on 13 th & 14 th May, 2025 through IT Portal)
4	Details of the violation(s)/contravention(s) committed or alleged to be committed;	The IT Authority vide reassessment / assessment orders has raised additional tax demands (including interest) of INR 341.86 crores under Section 147 read with Section 144C(3) / under section 143(3) read with Section 144C(3) of the Income-tax Act, 1961 ('the Act') on account of adjustment made u/s 80IC/80IE of the Act and disallowance of various expenditures u/s 37(1) of the Act.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible;	<p>The Company believes that the demands under the above referred Orders are not tenable in law. The Company has adequate factual and legal grounds to substantiate its position and does not expect any material impact on financials or operations of the Company due to the said orders. The Company would pursue appeal against the said orders under the applicable laws.</p> <p>In addition to above, in determining the aforesaid demand, the IT authorities have not considered credit of certain prepaid taxes pertaining to M/s. Lifestar Pharma Private Limited and Magnet Labs Private Limited, which have been merged with the Company w.e.f 01-04-2021, in relation to AY 2022-23. The Company is in the process of filing rectification petition for the aforesaid year, for reduction of demand to the extent of prepaid taxes along with interest thereon.</p>

MANKIND PHARMA LIMITED